Clinical and biologic activity of the famesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial

Blood

Volumn 97, Issue 11, 2001, Pages 3361-3369

  Karp, Judith E ^{a,b,c,d,e,f,g,h}   Lancet, Jeffrey E ^{a,b,c,d,e,f,g,h}   Kaufmann, Scott H ^{a,b,c,d,e,f,g,h}   End, David W ^{a,b,c,d,e,f,g,h}   Wright, John J ^{a,b,c,d,e,f,g,h}   Bol, Kees ^{a,b,c,d,e,f,g,h}   Horak, Ivan ^{a,b,c,d,e,f,g,h}   Tidwell, Michael L ^{a,b,c,d,e,f,g,h}   Liesveld, Jane ^{a,b,c,d,e,f,g,h}   Kottke, Timothy J ^{a,b,c,d,e,f,g,h}   Ange, Dawn ^{a,b,c,d,e,f,g,h}   Buddharaju, Laxmi ^{a,b,c,d,e,f,g,h}   Gojo, Ivana ^{a,b,c,d,e,f,g,h}   Edward Highsmith, W ^{a,b,c,d,e,f,g,h}   Belly, Robert T ^{a,b,c,d,e,f,g,h}   Hohl, Raymond J ^{a,b,c,d,e,f,g,h}   Rybak, Mary Ellen ^{a,b,c,d,e,f,g,h}   Thibault, Alain ^{a,b,c,d,e,f,g,h}   Rosenblatt, Joseph ^{a,b,c,d,e,f,g,h}  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c MAYO CLINIC   (United States)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

^e National Cancer Institute ^*

^f NATIONAL CANCER INSTITUTE   (United States)

^g Ortho Clinical Diagnostics Inc   (United States)

^h UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN FARNESYLTRANSFERASE INHIBITOR; TIPIFARNIB;

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; ATAXIA; BONE MARROW CELL; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FATIGUE; GENE MUTATION; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYPERTENSION; LEUKEMIA; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; POLYDIPSIA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VISUAL IMPAIRMENT; VOMITING;

EID: 0035383789     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.11.3361     Document Type: Article

References (55)

1. Buchner T, Hiddeman W, Wormann B, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood. 1999;93:4116-4124.
2. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the managemenet of acute myeloid leukemia in first remission. N Engl J Med. 1998;339:1649-1656.
3. Geller RB, Burke PJ, Karp JE, et al. A two-step timed sequential treatment for acute myelogenous leukemia. Blood, 1989;74:1499-1506.
4. Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1996;88:2841-2851.
5. Baudard M, Beauchamp-Nicoud A, Delmer A, et al. Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16-year period. Leukemia. 1999;13:1481-1490.
6. Hiddemann W, Kern W, Schoch C, et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol. 1999;17:3569-3576.
7. Karp JE, Smith MA. The molecular pathogenesis of treatment-induced (secondary) leukemias: foundations for treatment and prevention. Semin Oncol. 1997;24:103-113.
8. Levine E, Bloomfield C. Leukemias and myelodysplastic syndromes secondary to drug, radiation and environmental exposure. Semin Oncol. 1992;19:47-84.
9. Copelan EA, McGuire EA. The biology and treatment of acute lymphoblastic leukemia in adults. Blood. 1995;85:1151-1168.
10. Hoelzer D, Ludwig WD, Thiel E, et al. Improved outcome in adult B cell acute lymphoblastic leukemia. Blood. 1996;87:495-508.
11. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with Hyper-CVAD, a dose-intensive regimen, in adult acute lympyhocytic leukemia. J Clin Oncol. 2000;18:547-561.
12. Westbrook CA, Hooberman AL, Spino C, et al. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B study (8762). Blood. 1992;80:2983-2990.
13. Ito T, May WS. Drug development train gathering steam. Nat Med. 1996;2:403-404.
14. Karp JE. Acute leukemia: mechanisms of cell survival as targets for therapy (review). Int J Oncol. 1997;11:657-674.
15. McCubrey JA, May WS, Duronio V, Mufson A. Serine/threonine phosphorylation in cytokine signal transduction. Leukemia. 2000;14:9-21.
16. Rebollo A, Martinez-A, C. Ras proteins: recent advances and new functions. Blood. 1999;94: 2971-2980.
17. Egan SE, Giddings BW, Brooks MW, Buday L, Sizeland AM, Weinberg RA. Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation. Nature. 1993;363:45-51.
18. Li N, Batzer A, Daly R, et al. Guanine nucleotide-releasing factor hSos1 binds to Grb2 and links tyrosine kinases to Ras signalling. Nature. 1993; 363:85-88.
19. ras. J Biol Chem. 1994;51:32621-23625.
20. Gelb MH. Protein prenylation, et cetera: signal transduction in two dimensions. Science. 1997; 27:1750-1751.
21. Khosvari-Far R, Cox AD, Kato K, Der CJ. Protein prenylation: key to ras function and cancer intervention. Cell Growth Diff. 1992;3:461-469.
22. End DW. Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway. Invest New Drugs. 1999; 17:241-258.
23. Beaurpe DM, Kurzrock RA, RAS and leukemia: from basic mechanisms to gene-directed therapy. J Clin Oncol. 1999;17:1071-1079.
24. Du W, Lebowitz PF, Prendergast GC. Cell growth inhibition by farnesyltransferase inhibitors is mediated by a gain of granylgeranylated Rho B. Mol Cell Biol. 1999;19:1831-1840.
25. Reuter CWM, Morgan MA, Bergmann L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies. Blood. 2000;96:1655-1669.
26. Lebowitz PF, Prendergast GC. Non-Ras tragets of farnesyltransferase inhibitors: focus on Rho. Oncogene. 1998;17:1439-1445.
27. Jiang K, Coppola D, Crespo NC, et al. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cel Biol. 2000;20:139-148.
28. Hirsch-Ginsberg C, LeMaistre AC, Kantarjian H, et al. RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. Blood. 1990;76:1214-1219.
29. Paquette RL, Landaw EM, Pierre RV, et al. N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood. 1993;82:590-599.
30. Taylor JA, Sandler DP, Bloomfield CD, et al. Ras oncogene activation and occupational exposures in acute myeloid leukemia. J Natl Cancer Inst. 1992;84:1626-1632.
31. Bos JL, Verlaan-de Vries M, van der Eb AJ, et al. Mutations in N-ras predominate in acute myeloid leukemia. Blood. 1987;69:1237-1241.
32. Neubauer A, Dodge RK, George SL, et al. Prognostic importance of mutations in the ras protooncogenes in de novo acute myeloid leukemia. Blood. 1994;83:1603-1611.
33. Thom J, Molloy P, Iland H. SSCP detection of N-ras promoter mutations in AML patients. Exp Hematol. 1995;23:1098-1103.
34. Pendergast AM, Quilliam LA, Cripe LD, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 1993;75:175-185.
35. Pull L, Liu J, Gish G, et al. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J. 1994;13:764-773.
36. Rowinsky EK, Windle JJ, Von Hoff DD, Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol. 1999;17:3631-3652.
37. Zujewski J, Horak ID, Bol CJ, et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol. 2000;18:927-941.
38. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8: 813-819.
39. Fuery CJ, Impey HL, Roberts, et al. Detection of rare mutant alleles by restriction endonuclease-mediated selective-PCR: assay design and optimization. Clin Chem. 2000;46:620-624.
40. End DW, Chevalier K, Fanelli L, Kontoyianni M, Skrzat S, Wouters W. Unusual tight binding of R115777 to farnesyl protein transferase (FPT) allows for ex vivo measurement of FPT inhibition. In: Proceedings of the American Association for Cancer Research; April 1-5, 2000; San Francisco, CA, Abstract 1404.
41. Bradford MM. A rapid and sensitive method for quantitation of microgram quantitites of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
42. Shibasaki F, Price ER, Milan D, McKeon F. Role of kinases and the phosphates calcineurin in the nuclear shuttling of transcription factor NF-AT4. Nature. 1996;382:370-373.
43. Neckers L, Mimnaugh E, Schulte TW. The Hsp90 chaperone family. In: Latchman DS eds, Stress Proteins. New York, NY: Springer-Verlag; 1999:9-42.
44. Beck LA, Hosick TJ, Sinensky M. Isoprenylation is required for the processing of the lamin A precursor. J Cell Biol. 1990;110:1489-1499.
45. Britten CD, Rowinsky E, Yao SL, et al. The farnesyl protein transferase (FPTase) inhibitor L-778,123 in patients with solid cancers. In: Proceedings of the American Society of Clinical Oncology; May 15-18, 1999; Atlanta, GA. Abstract 155a.
46. Adjei AA, Davis JN, Ehrlichman C, Svingen PA, Kaufmann SH, Comparison of potential markers of farnesyltransferase inhibition. Clin Cancer Res. 2000;6:2318-2325.
47. Adjei AA, Erlichman C, Davis JN, et al. A phase 1 trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res. 2000;60:1871-1877.
48. Kaufmann SH. Expression of nuclear envelope lamins A and C in human myeloid leukemias. Cancer Res. 1992;52:2847-2853.
49. Kaufmann SH, Svingen PA, Gore SD, Armstrong DK, Cheng YC, Rowinsky EK. Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells. Blood. 1997;89: 2098-2104.
50. Sinensky M, Fantle K, Dalton M. An antibody which specifically recognizes prelamin A but not mature lamin A: application to detection of blocks in farnesylation-dependent protein processing. Cancer Res. 1994;54:3229-3232.
51. Loewinger L, McKeon F. Mutations in the nuclear lamin proteins resulting in their aberrant assembly in the cytoplasm. EMBO J. 1988;7:2301-2309.
52. Luna-Fineman S, Shannon KM, Lange BJ. Childhood monosomy 7: epidemiology, biology, and mechanistic implications. Blood. 1995;85:1985-1999.
53. Kinoshita T, Shirouza M, Kamiya A, Hashimoto K, Yokoyama S, Miyajima A. Raf/MAPK and rapamycin-sensitive pathways mediate the anti-apoptotic function of p21 Ras in IL-3 dependent hematopoietic cells. Oncogene. 1997;15:619-627.
54. Li BQ, Kaplan D, Kung HF, Kamata T. Nerve growth factor stimulation of the Ras-guanine nucleotide exchange factor and GAP activities. Science. 1992;256:1456-1459.
55. Virdee K, Vue L, Hemmings BA, Goemans C, Heumann R, Tolkovsky AM. Nerve growth factor-induced PKB/Akt activity is sustained by phosphoinositide 3-kinase dependent and independent signals in sympathetic neurons. Brain Res. 1999;837:127-142.